0001810705-20-000001.txt : 20201209 0001810705-20-000001.hdr.sgml : 20201209 20201209154706 ACCESSION NUMBER: 0001810705-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201209 DATE AS OF CHANGE: 20201209 EFFECTIVENESS DATE: 20201209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Transposon Therapeutics, Inc. CENTRAL INDEX KEY: 0001810705 IRS NUMBER: 843996895 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-382716 FILM NUMBER: 201377822 BUSINESS ADDRESS: STREET 1: 285 RIVERSIDE AVENUE STREET 2: SUITE 250 CITY: WESTPORT STATE: CT ZIP: 06880 BUSINESS PHONE: (949) 422-9676 MAIL ADDRESS: STREET 1: 285 RIVERSIDE AVENUE STREET 2: SUITE 250 CITY: WESTPORT STATE: CT ZIP: 06880 D 1 primary_doc.xml X0708 D LIVE 0001810705 Transposon Therapeutics, Inc. 2765 Sand Hill Road c/o Canaan Partners Menlo Park CA CALIFORNIA 94025 9494229676 DELAWARE None None Corporation true 2019 Dennis Podlesak 2765 Sand Hill Road c/o Canaan Partners Menlo Park CA CALIFORNIA 94025 Executive Officer Director Eckard Weber, M.D. 2765 Sand Hill Road c/o Canaan Partners Menlo Park CA CALIFORNIA 94025 Executive Officer Director Lynne R. Rollins 2765 Sand Hill Road c/o Canaan Partners Menlo Park CA CALIFORNIA 94025 Executive Officer Brent Ahrens 2765 Sand Hill Road c/o Canaan Partners Menlo Park CA CALIFORNIA 94025 Director John Pacifico 2765 Sand Hill Road c/o Canaan Partners Menlo Park CA CALIFORNIA 94025 Director Pharmaceuticals Decline to Disclose 06b false 2020-11-25 false true true true true Series A Preferred Stock and the underlying Common Stock issuable upon its conversion. false 0 45187328 45187328 0 false 10 0 0 0 false Transposon Therapeutics, Inc. /s/ Lynne R Rollins Lynne R Rollins Chief Financial Officer 2020-12-08